8-K: Oaktree Acquisition Corp. III Life Sciences Appoints Thomas Sweeney as New CFO Following Conigliaro's Resignation

Oaktree Acquisition Corp. III Life Sciences announced the resignation of CFO Courtney Conigliaro and the immediate appointment of Thomas Sweeney, a seasoned financial executive from Oaktree Capital Management, as her successor.

Summary

• Courtney Conigliaro resigned as Chief Financial Officer of Oaktree Acquisition Corp. III Life Sciences, effective June 3, 2025, to pursue other professional opportunities, with no disagreements cited.
• Thomas Sweeney was immediately appointed as the new Chief Financial Officer (principal accounting and principal financial officer), effective June 3, 2025.
• Mr. Sweeney, a Managing Director at Oaktree Capital Management, L.P., brings extensive experience in accounting, operations, and financial reporting, including roles at Oaktree's business development companies and prior experience at Fifth Street Asset Management and Deloitte & Touche.
• Mr. Sweeney will not receive compensation from the Company for his CFO services and is expected to enter into standard indemnity and letter agreements.
• The Board also confirmed Alvin Shih as the chair of the audit committee.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the smooth transition of the CFO role, the appointment of a highly experienced individual from the sponsor's parent company, and the fact that the new CFO will not be compensated by the company, which could be seen as a cost-saving measure. The outgoing CFO's departure was amicable.

Positives

• Appointment of Thomas Sweeney, an experienced financial professional from Oaktree Capital Management, L.P., as the new CFO.
• Mr. Sweeney will not be compensated by the Company for his services as CFO, potentially reducing overhead costs.
• The resignation of the former CFO, Courtney Conigliaro, was not due to any disagreements with the Board or management.

Negatives

• The departure of an existing Chief Financial Officer, Courtney Conigliaro, requires a transition period for the new appointee.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the expected execution of standard indemnity and letter agreements for the new CFO.

Management Comments

• Ms. Conigliaro’s resignation was not the result of any disagreements with the Board or management of the Company and she is resigning to pursue other professional opportunities.

Industry Context

This 8-K filing details a routine personnel change for a Special Purpose Acquisition Company (SPAC). Such changes are common in the lifecycle of public companies, including SPACs, as they prepare for or execute business combinations. The appointment of an executive from the sponsor's parent organization (Oaktree Capital Management) is a common practice for SPACs, leveraging internal talent and maintaining alignment.

Comparison to Industry Standards

• The appointment of a CFO directly from the sponsor's parent entity, Oaktree Capital Management, is a common practice among SPACs, such as those sponsored by other major financial institutions like Apollo Global Management or Blackstone, as it ensures close alignment with the sponsor's operational and financial oversight.
• The decision not to compensate the new CFO directly from the SPAC's funds for his services is a positive deviation from some industry norms, where SPACs often incur significant G&A expenses, potentially preserving more capital for a future business combination.
• The stated reason for the outgoing CFO's resignation ("to pursue other professional opportunities" and "not the result of any disagreements") aligns with standard, amicable executive transitions seen across the industry, contrasting with departures due to performance issues or strategic conflicts.

Management Changes

Corporate Governance

Related Party Transactions

• Thomas Sweeney, the newly appointed CFO, is a Managing Director within Oaktree Capital Management, L.P., which is the sponsor of Oaktree Acquisition Corp. III Life Sciences. He is expected to enter into an Indemnity Agreement and a Letter Agreement with the Company on the same terms as other directors and officers.

Stakeholder Impact

• Shareholders: The appointment of an experienced, uncompensated CFO from the sponsor's firm could be viewed positively, potentially reducing G&A expenses and ensuring strong financial oversight.
• Employees: No direct impact on general employees is indicated.
• Customers: Not applicable for a SPAC.
• Suppliers: Not applicable for a SPAC.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• Thomas Sweeney is expected to enter into an Indemnity Agreement and a Letter Agreement with the Company.

Key Dates

Recommendation

Keywords

Oaktree Acquisition Corp. III Life Sciences, OACCU, OACC, OACCW, CFO change, Chief Financial Officer, Thomas Sweeney, Courtney Conigliaro, Oaktree Capital Management, SPAC, Special Purpose Acquisition Company, corporate governance, audit committee